Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer
Détails
ID Serval
serval:BIB_B51990F50C8F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer
Périodique
Seminars in Oncology
ISSN
0093-7754 (Print)
Statut éditorial
Publié
Date de publication
06/1995
Volume
22
Numéro
3 Suppl 6
Pages
47-52
Notes
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review --- Old month value: Jun
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review --- Old month value: Jun
Résumé
Concomitant chemoradiotherapy holds promise in the therapy of advanced head and neck cancer. We have previously reported on the combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy administered on an alternate-week basis. In this ongoing study, we are testing the feasibility of adding continuous-infusion paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this combination. Background information and early clinical data are presented.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols/administration &
dosage/*therapeutic use
Clinical Trials
Combined Modality Therapy
Fluorouracil/administration & dosage
Head and Neck Neoplasms/*drug therapy/*radiotherapy
Humans
Hydroxyurea/administration & dosage
Infusions, Intravenous
Paclitaxel/administration & dosage
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
20/08/2019 16:23
Données d'usage
